Literature DB >> 35346491

Patterns and influence of nodal metastases after neoadjuvant chemoradiation and R0 resection in esophageal adenocarcinoma.

Caitlin A Harrington1, Rebecca A Carr1, Meier Hsu2, Kay See Tan2, Smita Sihag1, Prasad S Adusumilli1, Manjit S Bains1, Matthew J Bott1, James M Isbell1, Bernard J Park1, Gaetano Rocco1, Valerie W Rusch1, David R Jones1, Daniela Molena3.   

Abstract

OBJECTIVE: Little is known about the pattern of nodal metastases in patients with esophageal adenocarcinoma who have received neoadjuvant chemoradiation and undergone surgery. We sought to assess this pattern and evaluate its association with prognosis.
METHODS: All patients with esophageal adenocarcinoma who underwent neoadjuvant chemoradiation and R0 esophagectomy between 2010 and 2018 at our institution were included (n = 537). The primary objective was to evaluate the association of sites of lymph node metastases with disease-free survival. The number of nodal stations and individual sites of nodal metastases were evaluated first in univariable then in separate multivariable Cox regression models adjusted for clinical factors.
RESULTS: Of 537 patients, 193 (36%) had pathologic nodal metastases at the time of surgery; 153 (28%) had single-station disease, 32 (6.0%) had 2-station disease, and 8 (1.5%) had 3-station disease. The majority of patients with multiple positive nodal stations had positive nodes in the paraesophageal (93%) and/or left gastric stations (60%). Multivariable models controlling for clinical factors showed that an increasing number of positive nodal stations (hazard ratio, 1.59; 95% CI, 1.35-1.84; P < .01)-in particular, the subcarinal (hazard ratio, 2.78; 95% CI, 1.54-5.03; P < .01) and paraesophageal stations (hazard ratio, 2.0; 95% CI, 1.58-2.54; P < .01)-was associated with increased risk of recurrence.
CONCLUSIONS: One-third of patients who have undergone R0 resection for esophageal adenocarcinoma following induction chemoradiation therapy have metastatic lymph nodes. An increasing number of nodal stations, particularly paraesophageal and subcarinal metastases, were associated with increased risk of recurrence.
Copyright © 2022 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  esophageal adenocarcinoma; neoadjuvant chemoradiation; nodal metastases; surgery

Mesh:

Year:  2022        PMID: 35346491      PMCID: PMC9288545          DOI: 10.1016/j.jtcvs.2021.11.094

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   6.439


  17 in total

1.  The pattern of metastatic lymph node dissemination from adenocarcinoma of the esophagogastric junction.

Authors:  S M Dresner; P J Lamb; M K Bennett; N Hayes; S M Griffin
Journal:  Surgery       Date:  2001-01       Impact factor: 3.982

Review 2.  How Many Nodes Need to be Removed to Make Esophagectomy an Adequate Cancer Operation, and Does the Number Change When a Patient has Chemoradiotherapy Before Surgery?

Authors:  Jonathan C Yeung; Manjit S Bains; Arianna Barbetta; Tamar Nobel; Steven R DeMeester; Brian E Louie; Mark B Orringer; Linda W Martin; Rishindra M Reddy; Francisco Schlottmann; Daniela Molena
Journal:  Ann Surg Oncol       Date:  2019-10-11       Impact factor: 5.344

Review 3.  The extent of lymphadenectomy in esophageal resection for cancer should be standardized.

Authors:  Eliza R C Hagens; Mark I van Berge Henegouwen; Miguel A Cuesta; Suzanne S Gisbertz
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

4.  Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer.

Authors:  Thomas W Rice; Hemant Ishwaran; Mark K Ferguson; Eugene H Blackstone; Peter Goldstraw
Journal:  J Thorac Oncol       Date:  2016-10-31       Impact factor: 15.609

5.  Impact of Extent of Lymphadenectomy on Survival, Post Neoadjuvant Chemotherapy and Transthoracic Esophagectomy.

Authors:  Alexander W Phillips; Sjoerd M Lagarde; Maziar Navidi; Babbet Disep; S Michael Griffin
Journal:  Ann Surg       Date:  2017-04       Impact factor: 12.969

6.  The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent.

Authors:  Christophe Mariette; Guillaume Piessen; Nicolas Briez; Jean Pierre Triboulet
Journal:  Ann Surg       Date:  2008-02       Impact factor: 12.969

7.  Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors: A Prospective Nationwide Multicenter Study.

Authors:  Yukinori Kurokawa; Hiroya Takeuchi; Yuichiro Doki; Shinji Mine; Masanori Terashima; Takushi Yasuda; Kazuhiro Yoshida; Hiroyuki Daiko; Shinichi Sakuramoto; Takaki Yoshikawa; Chikara Kunisaki; Yasuyuki Seto; Shigeyuki Tamura; Toshio Shimokawa; Takeshi Sano; Yuko Kitagawa
Journal:  Ann Surg       Date:  2021-07-01       Impact factor: 12.969

Review 8.  Distribution of Lymph Node Metastases in Esophageal Carcinoma Patients Undergoing Upfront Surgery: A Systematic Review.

Authors:  Eliza R C Hagens; Mark I van Berge Henegouwen; Suzanne S Gisbertz
Journal:  Cancers (Basel)       Date:  2020-06-16       Impact factor: 6.639

9.  Is sentinel node mapping useful for esophageal cancer surgery?

Authors:  Soji Ozawa
Journal:  Ann Gastroenterol Surg       Date:  2019-01-15

10.  Survival Following Trimodality Therapy in Patients With Locally Advanced Esophagogastric Adenocarcinoma: Does Only a Complete Pathologic Response Matter?

Authors:  Smita Sihag; Tamar Nobel; Meier Hsu; Sergio De La Torre; Kay See Tan; Yelena Y Janjigian; Geoffrey Y Ku; Laura H Tang; Abraham J Wu; Steven B Maron; Manjit S Bains; David R Jones; Daniela Molena
Journal:  Ann Surg       Date:  2020-11-17       Impact factor: 12.969

View more
  1 in total

1.  Posttreatment Recurrence and Death Patterns in Patients with Advanced Esophageal Cancer.

Authors:  Xiangmei Zhang; Hui Wang; Dongwei He; Ming He; Xin Chen; Jidong Zhao
Journal:  Dis Markers       Date:  2022-07-09       Impact factor: 3.464

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.